Search results
Pfizer vs Moderna battle over COVID vaccine patents begins in UK
WSAU Wausau· 5 days agoBy Sam Tobin LONDON (Reuters) - Pfizer and BioNTech asked a London court to revoke rival Moderna's...
...BioNTech in London Patent Battle over Covid-19 Vaccines In Legal Showdown - Moderna...
Benzinga· 5 days agoModerna Inc. MRNA is set to clash with Pfizer Inc. PFE and BioNTech SE BNTX in a pivotal London...
GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology By Reuters
Investing.com· 3 days agoGSK said in the lawsuit that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent...
Analysts Expect Moderna's First-Quarter Sales To Plummet 95% — Is Moderna Stock A Sell?
Investor's Business Daily· 4 days agoModerna is rivaling vaccine makers Pfizer and Novavax. Still, the market for Covid boosters is...
Rival Covid-19 jab developers face off in High Court patent trial
PA Media: Science via Yahoo News· 5 days agoMr Mitcheson said that “it is clear that even on Moderna’s case the difference between the prior art...
COVID Vaccine Study Finds Small Signal of Seizure Risk in Young Kids
MedPage Today· 4 days agoResearchers also detected a statistical signal for seizures after vaccination with the BNT162b2 ...
COVID Shot Boosts Mucosal Immunity in Previously Infected People
MedPage Today· 5 days agoOnly 'traces' of spike-specific salivary antibodies found in vaccinated SARS-CoV-2-naive people
J.W. Cole Advisors Inc. Purchases 174 Shares of Moderna, Inc. (NASDAQ:MRNA)
ETF DAILY NEWS· 2 days agoJ.W. Cole Advisors Inc. lifted its stake in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 8.5% during the fourth quarter, according to the company in its most recent 13F filing ...
Uveitis History Linked to Recurrence After COVID Vaccination
MedPage Today· 3 days ago(HR 2.07, 95% CI 1.40-3.07). "These findings suggest that there was an elevated risk of uveitis...
Cwm LLC Has $11.77 Million Holdings in Moderna, Inc. (NASDAQ:MRNA)
ETF DAILY NEWS· 6 days agoCwm LLC lifted its holdings in shares of Moderna, Inc. (NASDAQ:MRNA – Free Report) by 27.1% during the fourth quarter, according to the company in its most recent Form 13F ...